The GP2 peptide: A HER2/neu-based breast cancer vaccine

Journal of Surgical Oncology

Volumn 105, Issue 5, 2012, Pages 452-458

  Clive, Kevin S ^a   Tyler, Josh A ^a   Clifton, G Travis ^a   Holmes, Jarrod P ^b   Ponniah, Sathibalan ^c   Peoples, George E ^a   Mittendorf, Elizabeth A ^d  

^a BROOKE ARMY MEDICAL CENTER   (United States)

^b NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^c UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

cancer; GP2; HER2 neu; immunotherapy; vaccine

Indexed keywords

CANCER VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GP2 PEPTIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANTIGEN PRESENTING CELL; BREAST CANCER; CANCER IMMUNIZATION; CANCER RECURRENCE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG SAFETY; DRUG SCREENING; EX VIVO STUDY; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSTIMULATION; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RECURRENCE RISK; REVIEW;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; DIMERIZATION; FEMALE; GPI-LINKED PROTEINS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HLA-A2 ANTIGEN; HUMANS; IMMUNOGLOBULIN G; IMMUNOTHERAPY; MUCIN-1; PEPTIDE FRAGMENTS; RECEPTOR, ERBB-2;

EID: 84859018209     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21723     Document Type: Review

References (34)

1. Romond EH, Perez EA, Bryant J, et al.: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Eng J Med 2005; 353: 1673-1684. (Pubitemid 41464706)
2. Slamon DJ, Godolphin W, Jones LA, et al.: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-712. (Pubitemid 19147683)
3. Peoples GE, Holmes JP, Hueman MT, et al.: Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res 2008; 14: 797-803. (Pubitemid 351231162)
4. Peoples GE, Goedegebuure PS, Smith R, et al.: Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci USA 1995; 92: 432-436.
5. Mittendorf EA, Storrer CE, Foley RJ, et al.: Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial. Cancer 2006; 106: 2309-2317. (Pubitemid 43787653)
6. Itoh K, Platsoucas CD, Balch CM,: Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor. J Exp Med 1988; 168: 1419-1441. (Pubitemid 18264875)
7. Topalian SL, Solomon D, Rosenberg SA,: Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol 1989; 142: 3714-3725. (Pubitemid 19137511)
8. Klehmann WT, Müller E, Schütt KH, et al.: Lysis of human melanoma cells by autologous cytolytic T cell clones. Identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens. J Exp Med 1989; 170: 797-810.
9. Crowley NJ, Darow TL, Quinn-Allen MA, et al.: MHC-restricted recognition of autologous melanoma by tumor-specific cytotoxic T cells. Evidence for restriction by a dominant HLA-A allele. J Immunol 1991; 146: 1692-1699.
10. Pandolfi F, Boyle LA, Trentin L, et al.: Expression of HLA-A2 antigen in human melanoma cell lines and its role in T-cell recognition. Cancer Res 1991; 51: 3164-3170.
11. Peoples GE, Goedegebuure PS, Andrews JV, et al.: HLA-A2 presents shared tumor-associated antigens derived from endogenous proteins in ovarian cancer. J Immunol 1993; 151: 5481-5491. (Pubitemid 23332358)
12. Brossart P, Stuhler G, Flad T, et al.: Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res 1998; 58: 732-736. (Pubitemid 28099485)
13. Peiper M, Goedegebuure PS, Linehan DC, et al.: The HER2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes. Eur J Immunol 1997; 27: 1115-1123. (Pubitemid 27197213)
14. Yoshino I, Peoples GE, Goedegebuure PS, et al.: HER2/neu-derived peptide(s) are shared antigens among human non-small cell lung cancer and ovarian cancer. Cancer Res 1994; 54: 3387-3390. (Pubitemid 24225955)
15. Hsu FJ, Benike C, Fagnoni F, et al.: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996; 2: 52-58. (Pubitemid 26028073)
16. Nestle FO, Alijagic S, Gilliet M, et al.: Vaccination of melanomal patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4: 328-332. (Pubitemid 28144092)
17. Brossart P, Wirths S, Stuhler G, et al.: Induction of cytotoxic T-lymphocyte responses in vivo after vaccination with peptide-pulsed dendritic cells. Blood 2000; 96: 3102-3108.
18. Dees EC, McKinnon KP, Kuhns JJ, et al.: Dendritic cells can be rapidly expanded ex vivo and safely administered in patients with metastatic breast cancer. Cancer Immunol Immunother 2004; 53: 777-785. (Pubitemid 39149904)
19. Mittendorf EA, Gurney JM, Storrer CE, et al.: Vaccination with a HER2/neu peptide induces intra- and inter-antigenic epitope spreading in early stage breast cancer patients. Surgery 2006; 139: 407-418.
20. Carmichael MG, Benavides LC, Holmes JP, et al.: Results of the first phase I clinical trial of the HER2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study 1-04. Cancer 2010; 116: 292-301.
21. Clifton GT, Holmes JP, Perez SA, et al.: Interim analysis of a randomized phase II study of the novel HER2/Neu peptide (GP2) vaccine to prevent breast cancer recurrence: United States Military Cancer Institute Clinical Trials Group study I-05. [Abstract #5110]. Cancer Res 2009; 69: 802s.
22. Hung K, Hayashi R, Lafond-Walker A, et al.: The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 1998; 188: 2357-2368. (Pubitemid 29028508)
23. Knutson KL, Schiffman K, Cheever MA, et al.: Immunization of cancer patients with a HER2/neu, HLA-A2 peptide, p369-377, results in short-live peptide-specific immunity. Clin Cancer Res 2002; 8: 1014-1018. (Pubitemid 34517634)
24. Knutson KL, Schiffman K, Disis ML,: Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest 2001; 107: 477-484. (Pubitemid 32167994)
25. Knutson KL, Disis ML,: Augmenting T helper cell immunity in cancer. Curr Drug Targets 2005; 5: 365-371. (Pubitemid 41722379)
26. Mittendorf EA, Holmes JP, Murray JL, et al.: CD4+ T cells in antitumor immunity: Utility of an Ii-Key HER2/neu hybrid peptide vaccine. Exp Opin Biol Ther 2009; 9: 71-78.
27. Holmes JP, Benavides LC, Gates JD, et al.: Results of the first phase I clinical trial of the novel Ii-Key hybrid preventive HER2/neu peptide (AE37) vaccine: United States Military Cancer Institute Clinical Trials Group Study I-03. J Clin Oncol 2008; 26: 3426-3433.
28. Castilleja A, Ward NE, O'Brian CA, et al.: Accelerated HER-2 degradation enhances ovarian tumor recognition by CTL: Implications for tumor immunogenicity. Mol Cell Biochem 2001; 217: 21-33. (Pubitemid 32184453)
29. Drebin JA, Link VC, Stern DF, et al.: Down-modulation of an oncogene protein product and revision of the transformed phenotype by monoclonal antibodies. Cell 1985; 41: 697-706.
30. Hurwitz E, Stancovski L, Sela M, et al.: Suppression and promotion of tumor growth by monoclonal antibodies to Erb-2 differentially correlate with cellular uptake. Proc Natl Acad Sci USA 1995; 92: 3352-3357.
31. Klapper LN, Waterman H, Sela M, et al.: Tumor-inhibitory antibodies to HER2/erb-2 may act by recruiting c-cbl and enhancing ubiquination of HER2. Cancer Res 2000; 60: 3384-3388. (Pubitemid 30482151)
32. zum Büschenfelde CM, Hermann C, Schmidt B, et al.: Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells. Cancer Res 2002; 62: 2244-2247. (Pubitemid 34411698)
33. Mittendorf EA, Storrer CE, Shriver CD, et al.: Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer. Ann Sur Oncol 2006; 13: 1085-1098. (Pubitemid 44337968)
34. Disis ML, Wallace DR, Gooley TA, et al.: Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. J Clin Oncol 2009; 27: 4685-4692.